The U.S. Food and Drug Administration has denied approval for PTC Therapeutics' oral medication for a rare genetic disorder ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) ...

The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid ...

"We are, of course, disappointed by the FDA's decision to not approve vatiquinone," said Matthew Klein, PTC's chief executive, who noted that the FDA is seeking another 'adequate and well-controlled' ...

Votoplam (PTC518) for Huntington's Disease shows promising phase 2 results; a key FDA meeting in Q4 2025 could enable ...

PTC Therapeutics is stuck with uncertainty stretching through 2030. Here's why the stock remains a long-term avoid.

PTC is demonstrating robust growth and consistent profitability, and analyst sentiment has grown more favorable recently.

FDA states substantial evidence of efficacy was not demonstrated.

With strong share price gains and significant hedge fund interest, PTC Inc. (NASDAQ:PTC) secures a spot on our list of the 11 ...

FDA rejected PTC Therapeutics' vatiquinone for Friedreich's ataxia, citing insufficient efficacy data and requiring another ...

The U.S. Food and Drug Administration has declined to approve PTC Therapeutics' drug to treat a rare genetic disorder with ...